A Non-Interventional Study Evaluating Rheumatoid Arthritis Participants Treated With Tocilizumab (RoActemra/Actemra)

Time frame: 6 months

Population: Enrolled participants.

Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in RA. The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores range from 0 to 76, with higher scores indicating increased disease activity.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR; in millimeters per hour \[mm/hour\]) and global health assessment (participant-rated global assessment of disease activity using 10-mm visual analog assessment \[VAS\]); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

The HAQ is a participant self-reported questionnaire for assessing the extent of the participant's functional ability. It consists of 20 questions in 8 categories (dressing and grooming, rising, eating, walking, reach, grip, hygiene, and carrying out daily activities). Each question has 4 response options, ranging from 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. The HAQ scale is an average of all the scores and ranges from 0 to 3, where higher scores represent higher disease activity.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

The Patient Global Assessment of disease activity provides an overall assessment of how RA affects the participant using a visual analogue score, where 0 indicates they are managing very well and 100 indicates they are managing very poorly. A decrease in the score indicates improvement.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

Time frame: 6 months

Population: Enrolled participants.

Percentage of participants achieving a response by EULAR category, including moderate, good, or no response. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline \<-1.2 with a DAS28 score ≤3.2; Moderate response: change from baseline \<-1.2 with DAS28 scores \>3.2 to ≤ 5.1 or \>5.1, or a change from baseline \<-0.6 to ≥-1.2 with DAS28 scores ≤3.2 and \>3.2 to ≤5.1; No response: change from baseline \<-0.6 to ≥-1.2 with DAS28 score \>5.1, or a change from baseline ≥-0.6 with DAS28 scores ≤3.2, \>3.2 to ≤ 5.1, or \>5.1.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

Percentage of participants achieving a response by EULAR category, including moderate, good, or no response. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline \<-1.2 with a DAS28 score ≤3.2; Moderate response: change from baseline \<-1.2 with DAS28 scores \>3.2 to ≤ 5.1 or \>5.1, or a change from baseline \<-0.6 to ≥-1.2 with DAS28 scores ≤3.2 and \>3.2 to ≤5.1; No response: change from baseline \<-0.6 to ≥-1.2 with DAS28 score \>5.1, or a change from baseline ≥-0.6 with DAS28 scores ≤3.2, \>3.2 to ≤ 5.1, or \>5.1.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

Time frame: Baseline

Population: Enrolled participants.

An AESI includes serious/medically significant infections; opportunistic infections; cases of elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST), in combination with either elevated bilirubin or clinical jaundice; suspected transmission of an infectious agent by the study drug; myocardial infarction /acute coronary syndrome; gastrointestinal perforations; malignancies; anaphylaxis / hypersensitivity reactions (including injection site reactions); demyelinating disorders; stroke; serious/medically significant bleeding events; or serious/medically significant hepatic events.

Time frame: 6 months

Population: Enrolled participants.

ACR response was calculated based on total joint count evaluation and other clinical and laboratory assessments. A positive ACR20 response required at least a 20% improvement (reduction) compared to baseline in swollen joint count (28 joints) and tender joint count (28 joints) and at least 3 of the following 5 assessments: patient's global assessment of pain, participant's global assessment of disease activity (PGH), physician's global assessment of disease activity (PhGH) (all 3 assessed at 0 \[good\] to 100 mm \[worst\] VAS scale); participant assessment of disability measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessed on a 0 to 3 scale, where higher scores represented higher disease activity); acute phase reactant (CRP or ESR). A reduction in the level of and acute phase reactants was considered an improvement. ACR50 and ACR70 require a 50% and 70% improvement from baseline, respectively.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

Time frame: 6 months

Population: Enrolled participants.

Time frame: 6 months

Population: Enrolled participants.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

Simplified Disease Activity Index (SDAI) is an index for measuring disease activity in RA and has a good correlation with the DAS28. The index is calculated using the following formula: SDAI: swollen joint count (SJC28) + tender joint count (TJC28) + physician global assessment (PGA) (10 cm visual analogue scale \[VAS\]) + PhGA (10 cm VAS + C-Reactive Protein (CRP) in milligrams/liter (mg/L). VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Scores range from 0 to 86, with higher scores also indicating increased disease activity.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

The VAS-fatigue provides an overall assessment of the level of fatigue that the participant is experiencing using a visual analogue score, where 0 indicates no fatigue, and 100 indicates extreme fatigue. A decrease in the score indicates improvement.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

Morning stiffness was defined by the time elapsed between the time of usual awakening (even if not in the morning) and the time the participant was as limber as he/she would be during a day involving typical activities. Morning stiffness was assessed on a 100 mm VAS, where 0= none and 100= very severe.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.

The VAS-Pain provides an overall assessment of the severity of pain that the participant is experiencing using a visual analogue score, where 0 indicates no pain and 100 indicates unbearable pain. A decrease in the score indicates improvement.

Time frame: 6 months

Population: Enrolled participants who were evaluable for this outcome measure.